80469
document
Inhibition of spontaneous platelet aggregation and adhesion by indobufen ( K 3920 ) . A randomized , double-blind crossover study on platelet , coagulation and fibrinolysis function tests . In a randomized double-blind crossover study in 12 patients with atherosclerotic disease , the effect of 2 dosages ( 100 and 200 mg twice daily ) of indobufen , a new synthetic inhibition of platelet aggregation , on some platelet functions , coagulation and fibrinolysis tests was investigated . Regardless of the dosage used , indobufen was shown to induce a prompt normalization of the enhanced platelet aggregation of these patients . The effect lasted for the entire period of drug administration and in 50 % of patients a normal platelet aggregation was maintained until the fourth day after discontinuation of the drug . Indobufen was also able to reduce platelet adhesiveness and to lengthen bleeding time , especially when the higher dosage was used .
80470
Intervention_Pharmacological
indobufen ( K 3920 ) .
80471
Intervention_Pharmacological
indobufen
80472
Intervention_Pharmacological
indobufen
80473
Intervention_Pharmacological
Indobufen
80474
Outcome_Physical
platelet aggregation and adhesion
80475
Outcome_Physical
platelet functions , coagulation and fibrinolysis tests
80476
Outcome_Physical
enhanced platelet aggregation
80477
Outcome_Physical
platelet adhesiveness
80478
Outcome_Physical
bleeding time
80479
Participant_Sample-size
12
80480
Participant_Condition
atherosclerotic disease